



Press Release

Cipla India concludes the deal with Cipla Medpro South Africa

India, Mumbai, 16th July 2013:

Cipla Limited ("Cipla"), one of India's leading generic pharmaceutical companies today announced that it has completed the acquisition of 100% of the issued shares of Cipla Medpro South Africa Limited ("Medpro"), for an aggregate consideration of ZAR 4507mn (INR 2707cr). The listing of the shares of Medpro on the JSE Ltd has been terminated from the commencement of business on 16th July 2013.

Commenting on the successful acquisition, **Mr. Subhanu Saxena, MD & Global CEO, Cipla said,** "This investment is aligned with Cipla's strategy to ascend the value-chain by managing a front-end sales force in a market outside India. The acquisition aims to further strengthen the Cipla's commitment to South Africa and the broader African continent. The integrated business will compete more effectively in the changing local and global pharmaceutical environments and as such there will be an increasing focus on key African markets."

Mr. Saxena further added, "Spanning nearly two decades, Cipla and Medpro enjoyed a long-standing symbiotic relationship and the acquisition will strengthen Medpro's position in the South African pharmaceutical market by leveraging Cipla's wide range of product portfolio and technological expertise. This will bring tangible benefits to consumers in South Africa, and increasingly the rest of Africa."

About Cipla

Cipla laid the foundation for the Indian pharmaceutical industry in 1935, with the vision to make India self-reliant in healthcare. Over the years, Cipla has emerged as one of the most respected names not just in India but worldwide. Its state-of-the-art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. The company has over 34 manufacturing facilities across India, and manufactures 2,000+ products in 65 therapeutic categories.

With a turnover of over US \$ 1.5 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. For more information, visit www.cipla.com

About Cipla Medpro

Cipla Medpro South Africa Ltd is the third largest South African pharmaceutical company founded in 1993 and is a leading provider of chronic medicines to the public and private sectors. Cipla Medpro manufactures world class pharmaceuticals at cost-effective prices, making quality medicines affordable to all South Africans. Visit www.ciplamedpro.co.za for more information.

Media Contact:

Jaisingh Balakrishnan
Corporate Communications
Mob: (+91) 9833836185
E Mail: jaisingh.krishnan@cipla.com

Ajay Luharuka
Corporate Strategy
Direct No: +91 22 23035435
E Mail: ajay@cipla.com